作者: Cathy Y. Zhao , Dedee F. Murrell
DOI: 10.1007/S13671-016-0140-Y
关键词:
摘要: Autoimmune blistering diseases (AIBD) are a group of rare yet potentially fatal disorders characterised by autoantibodies directed towards structural components the skin and mucosal membranes. The management AIBDs needs to be tailored based on disease subtype, severity extent disease, patient comorbidities, treatment-related side effects, cost accessibility therapy, quality life. For most AIBDs, international consensus regarding treatment guidelines high randomised controlled trials (RCTs) lacking. Treatment generally consists corticosteroids combined with adjuvant anti-inflammatory or immunosuppressive therapies. Biological treatments including anti-CD20 agent such as rituximab in appear mechanistically promising.